It is currently Sun Apr 20, 2014 7:04 pm

News News of Rituxan (Rituximab)

Site map of Rituxan (Rituximab) » Forum : Rituxan (Rituximab)

A board to discuss the anticipated multiple sclerosis treatment Rituxan.

NIH study for SPMS underway on experimental drug Rituximab

There are currently no effective treatments for people with secondary-progressive MS who do not experience relapses or who do not have “active” lesions on MRI, however researchers at the National Institutes of Health in Bethesda, Maryland are evaluating the safety and effectiveness of Rituximab (trade names Rituxan and MabThera) – a new experimental drug for treating MS. In this study, Rituximab be delivered intravenously and directly into the cerebrospinal fluid by lumbar puncture of about ...
Read more : NIH study for SPMS underway on experimental drug Rituximab | Views : 440 | Replies : 0


Moving to Rituxan from Tecfidera

I have been battling MS since 1999. Finally got diagnosed with SPMS. I have been without a spleen since 1974 due to trauma. Going for Rituxan from Tecfidera. Any tips or advice from those who have tried Rituxan? I know that we have to be weary of severe leucopenia and hepatitis B antibodies.
Read more : Moving to Rituxan from Tecfidera | Views : 664 | Replies : 9


FDA adds boxed warning to Rituxan

Boxed Warning of HBV Risk Added to Rituxan
http://www.medpagetoday.com/PublicHealt ... eral/41864

The FDA announced today that rituximab (Rituxan) and ofatumumab (Arzerra) will now carry a boxed warning of the risk for immunosuppression-related reactivation of hepatitis B virus (HBV).

The two agents are anti-CD20-directed monoclonal antibodies used to treat chronic lymphocytic leukemia. Rituximab also is used for non-Hodgkin's lymphoma, rheumatoid arthritis, vasculitis, and other conditions.

Reactivation of HPV can occur ...
Read more : FDA adds boxed warning to Rituxan | Views : 481 | Replies : 0


Immortalized mser B cells produce brain autoantibodies

Couldn't fit a decent title in...sorry if that was a bit misleading.

Immortalised B cell lines from multiple sclerosis patients produce autoreactive monoclonal antibodies
http://registration.akm.ch/einsicht.php ... KEN_ID=900
B cells and oligoclonal antibodies are present in the cerebrospinal fluid (CSF) of multiple sclerosis (MS) patients but their target antigens remain unknown. The focus of this study was to produce autoantibodies of MS patients based on B cell immortalization and to ...
Read more : Immortalized mser B cells produce brain autoantibodies | Views : 580 | Replies : 2


Autoantigen induced clonal expansion in immortalized B cells

Autoantigen induced clonal expansion in immortalized B cells from the peripheral blood of multiple sclerosis patients
http://www.sciencedirect.com/science/ar ... 2813001343
We studied Ig heavy chain (VDJ) sequences and antigen reactivity of 412 immortalized B cell lines from the peripheral blood of 10 multiple sclerosis (MS) patients, 4 clinically isolated syndrome (CIS) patients and 6 healthy controls (HCs). 78/238 (32.8%) MS and CIS B cell lines were part of 9 clonally ...
Read more : Autoantigen induced clonal expansion in immortalized B cells | Views : 517 | Replies : 0


Rituximab kills auto reactive plasma B cells

I was worried about the ebv infected plasma cells escaping rituxan because plasma cells don't usually express cd20. Looks like there is a chance rituxan might kill those buggers after all. :)

Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis
http://m.pnas.org/content/107/10/4658.full
Read more : Rituximab kills auto reactive plasma B cells | Views : 460 | Replies : 0


MS-b cell tolerance defect-rituximab efficacy

In a study of 7 ms patients (small!), all tested positive for peripheral B cell tolerance defect. Two also tested positive for central B cell tolerance defect. Study authors propose those with only peripheral B cell tolerance defect will respond favorably and for a longer term to treatment with rituximab. They surmise the new B cells will be normal in those with peripheral B cell tolerance issues...and B cells will continue to be abnormal in ...
Read more : MS-b cell tolerance defect-rituximab efficacy | Views : 571 | Replies : 0


My first Rituxan infusion

After waiting 6 months for approval, being on no meds during the wait, I am excited to start the Rituxan. However, I am anxious/nervous about the infusion. Will I be able to return to work the next day? Did anyone develop adverse side effects? I started on copaxone and did well for over a year. Then one night after an injection i quickly developed anyphylaxis (?) and had to go to the local er. not ...
Read more : My first Rituxan infusion | Views : 1033 | Replies : 6


Rituximab iv and intrathecal with valtrex

Hopefully I am jcv negative so we can proceed in October.

If all goes well, we'll be following standard protocol for ebv-related post transplant lymphoproliferative disease, systemically and in CNS. 375mg/m2 i.v. and 15mg i.t. (might increase) once a week for four weeks. It will all be done in his office. How convenient. :D

Have I mentioned I love my neuro?
Read more : Rituximab iv and intrathecal with valtrex | Views : 3126 | Replies : 77


Rituximab Relation to ocrelizumab

It turns out that Rituximab patent expires in the US in 2015. This means that, by the time the phase III is over, the patent will be over too. So, no profit then in doing such an investment. To surpass this inconvenience Genentech invented a new drug, antiCD20 as well, but humanized (Rituximab is chimeric), called Ocrelizumab, and started the whole process again. Then, obviously, we got a phase II trial with ocrelizumab in MS. ...
Read more : Rituximab Relation to ocrelizumab | Views : 1065 | Replies : 1


 

Login  •  Register


Statistics

Total posts 216464 • Total topics 22115 • Total members 13908